doi: 10.3390/antiox11010125 40 Gonzalez-LiencresCTasCBrownECErdinSOnurECubukcogluZet al
Noom's physician-designed program employs a "low and slow" titration approach with microdoses that are a fraction of conventional maintenance doses
A phase Ib trial with a 4-week subcutaneous administration of either 10 mg or 15 mg tirzepatide once weekly in subjects with T2D led to a significant reduction in fasting plasma glucose concentrations (LSM difference [95% CI]: 49.12 mg/dl [78.14, 20.12] and 43.15 mg/dl [73.06, 13.21], respectively) and to reductions in body weight (LSM difference [95% CI]: 2.62 kg [3.79, 1.45] and 2.07 kg [3.25, 0.88], respectively
That means Lilly is gaining ground, but Novo is not a weakened fringe player
In contrast, animal studies showed relative safety when exposure was during early gestation, whereas exposure in later in pregnancy was associated with dilation of renal pelvis and tubules